Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224834 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL18709165 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL25984102 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL18858339 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL17949819 | 0.90 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL10092579 | 0.89 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL26477155 | 0.88 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL4890742 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL24591323 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL27489823 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-9700633-B2 | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof | JENKEM TECHNOLOGY CO., LTD., TIANJIN BRANCH (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20150359900-A1 | CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF | JENKEM TECHNOLOGY CO. LTD., TIANJIN BRANCH (CN) | 2015-12-17 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-7988950-B2 | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents | BRACCO IMAGING S.P.A. (IT) | 2011-08-02 | — | — | US | disclosed |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | BRACCO IMAGING SPA (IT) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | ALDH1A1 2161/4885MAPK1 1264/4885L3MBTL1 1122/4885 |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | SLC40A1, SLC67A1, SLC19A1 | ALDH1A1 2186/4885MAPK1 2492/4885L3MBTL1 3245/4885 |
| US-20150359900-A1 | CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF | SLC7A1, NPPA, PEPD | ALDH1A1 2543/4885MAPK1 2262/4885L3MBTL1 1271/4885 |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | ALDH1A1 1647/4885MAPK1 3812/4885L3MBTL1 1678/4885 |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | RXFP1, SLC5A7, SLC40A1 | ALDH1A1 2843/4885MAPK1 3469/4885L3MBTL1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.